Title
Population-Based Assessment of Hypertension Epidemiology and Risk Factors among HIV-Positive and General Populations in Rural Uganda.

Permalink
https://escholarship.org/uc/item/2726t12d

Journal
PloS one, 11(5)

ISSN
1932-6203

Authors
Kwarisiima, Dalsone
Balzer, Laura
Heller, David
et al.

Publication Date
2016

DOI
10.1371/journal.pone.0156309

Peer reviewed
Population-Based Assessment of Hypertension Epidemiology and Risk Factors among HIV-Positive and General Populations in Rural Uganda

Dalsone Kwarisiima1, Laura Balzer2,3, David Heller3a, Prashant Kotwani3, Gabriel Chamie3, Tamara Clark3, James Ayieko4, Florence Mwangwa1, Vivek Jain3, Dathan Byonanebye1, Maya Petersen5, Diane Havlir3, Moses R. Kamya1,6

1 Infectious Diseases Research Collaboration, Kampala, Uganda, 2 Harvard University, Boston, Massachusetts, United States of America, 3 University of California, San Francisco, San Francisco, California, United States of America, 4 Kenya Medical Research Institute (KEMRI), Nairobi, Kenya, 5 University of California, Berkeley, California, United States of America, 6 Makerere University College of Health Sciences, Kampala, Uganda

Abstract

Background

Antiretroviral therapy scale-up in Sub-Saharan Africa has created a growing, aging HIV-positive population at risk for non-communicable diseases such as hypertension. However, the prevalence and risk factors for hypertension in this population remain incompletely understood.

Methods

We measured blood pressure and collected demographic data on over 65,000 adults attending multi-disease community health campaigns in 20 rural Ugandan communities (SEARCH Study: NCT01864603). Our objectives were to determine (i) whether HIV is an independent risk factor for hypertension, and (ii) awareness and control of hypertension in HIV-positive adults and the overall population.

Results

Hypertension prevalence was 14% overall, and 11% among HIV-positive individuals. 79% of patients were previously undiagnosed, 85% were not taking medication, and 50% of patients on medication had uncontrolled blood pressure. Multivariate predictors of hypertension included older age, male gender, higher BMI, lack of education, alcohol use, and residence in Eastern Uganda. HIV-negative status was independently associated with higher odds of hypertension (OR 1.2, 95% CI: 1.1–1.4). Viral suppression of HIV did not significantly predict hypertension among HIV-positives.
Significance

The burden of hypertension is substantial and inadequately controlled, both in HIV-positive persons and overall. Universal HIV screening programs could provide counseling, testing, and treatment for hypertension in Sub-Saharan Africa.

Introduction

Hypertension (HTN) is the leading risk factor for cardiovascular and cerebrovascular mortality worldwide [1], and is thought to be responsible for 45% of deaths due to heart disease and 51% of deaths due to stroke in 2013 [2,3]. The age-adjusted adult prevalence of HTN in Sub-Saharan Africa is the highest in the world at approximately 46% [3]. The World Health Organization (WHO) projects that non-communicable diseases (NCDs), such as HTN, will cause 50% of total mortality in Sub-Saharan Africa in 2015, and 61% by 2030 [4,5]. Although risk factors for HTN are well-characterized in developed countries [3], they remain incompletely understood in Sub-Saharan Africa [6]. One study from Ethiopia reported older age, male sex, family history, physical inactivity, salt-rich diet, and obesity as HTN risk factors [7]. Similar results were recently reported in Uganda, but with a limited sample size (N < 4000) [8,9].

The HIV epidemic in Sub-Saharan Africa has further complicated efforts to both understand and control the HTN burden in the region. HIV is also more prevalent in Sub-Saharan Africa than anywhere else in the world [10]. Rapid scale-up of anti-retroviral therapy (ART) has resulted in declines in HIV-related morbidity and mortality [10–12]. With this success has come an aging population of individuals living with HIV who are susceptible to NCDs such as HTN [13]. Moreover, whether ART medications or HIV itself interact with traditional risk factors for HTN remains unclear [14]. One study in Italy reported higher HTN prevalence in HIV-positive compared to HIV-negative adults [15]; others, also in developed countries, reported no significant association between HIV status and HTN [14,16,17]. Three studies in Sub-Saharan Africa found HIV infection to be associated with lower prevalence of HTN [8,18,19], but others reported HIV infection to be positively associated with cardiovascular disease as a whole [20–22]. Thus far, data on the HIV-HTN relationship have been largely clinic-based, and often lacked HIV-negative comparison groups [13].

In this study, we sought to characterize the prevalence and awareness of HTN among HIV-positive persons and the general population, in a large population-based sample from rural Uganda communities. We also sought to determine risk factors for HTN in both populations.

Materials and Methods

Study Setting and Background

We studied 20 non-adjacent rural Ugandan communities (ten in Western Uganda and ten in Eastern Uganda) enrolled in the Sustainable East Africa Research in Community Health (SEARCH) Study (NCT01864603) [23]. Each community has 16–25 villages and approximately 10,000 persons (~50% adults age ≥18 years). As described previously [24–28], each SEARCH study community held a census to enumerate households and obtain consent from household heads, followed by a community health campaign (CHC) offering multi-disease screening, treatment and linkage to care. Each adult (aged ≥18) participant was offered point-of-care screening for HTN, HIV, and diabetes; persons screening positive for any condition were linked to care at a nearby health center. We measured participants’ height (to nearest 0.1
cm), and weight (to nearest kilogram). We also collected demographic and behavioral information, including age, gender, occupation, marital status, education level, and alcohol use.

**Measurement of Blood Pressure, Blood Glucose and HIV Serostatus**

We measured blood pressure (BP) on all adults using electronic sphygmomanometers. Participants with an elevated initial pressure (systolic BP ≥140 mmHg or diastolic BP ≥ 90 mmHg) had two repeat measurements ≥1 minute apart. Additionally, all adult participants were asked whether they were aware of a prior diagnosis of HTN and, if so, whether they had taken antihypertensive medications (prescribed at a health facility) in the past three months. Each adult participant also underwent a finger-prick point-of-care random blood glucose test (Optium-Abbott), with diabetes defined as a random blood sugar >11 mmol/L (196 mg/dL) and pre-diabetes defined as a random blood sugar >7 mmol/L (126 mg/dL) but ≤ 11 mmol/L. HIV rapid testing was performed and interpreted according to the Uganda national algorithm [29]. HIV-positive participants had fingerprick blood drawn for viral load measurement using previously described methods [30]. All HIV-positive persons, regardless of prior knowledge of HIV status or ART use, were offered a first-line ART regimen of efavirenz with emtricitabine and tenofovir disoproxil fumarate at their local health center, as detailed in the SEARCH study protocol [23].

**Classification of HTN and risk factors**

We defined HTN as a systolic BP ≥140 or diastolic BP ≥ 90 mm Hg on all three measurements as per World Health Organization (WHO) guidelines [31], or self-reported current use of antihypertensives. Stage 1 HTN was defined as highest systolic BP <160 mmHg and highest diastolic BP <100 mmHg; other hypertensive participants were defined as stage 2 [32]. We used body mass index (BMI) to classify participants as underweight or normal weight (< 25 kg/m²), overweight (25.0–29.9 kg/m²), or obese (≥ 30 kg/m²). We classified alcohol use (yes/no) based on self-report of current intake. We classified marital status as ‘single’ for persons reporting no current/prior marriage, and ‘non-single’ otherwise (e.g., currently married, divorced, or widowed). We calculated a household wealth index using principal components analysis [33], based on ownership of livestock (cows, goats, and poultry) and household items (clock, radio, television, phone, refrigerator, bicycle, motorcycle, and electricity).

**Estimation of Prevalence and Predictors of Hypertension**

All CHC participants aged ≥ 18 years and resident to the 20 selected communities were included in the analysis. We computed the prevalence of HTN both within the population sample, and normalized to the WHO standard population distribution [34]. We used logistic regression, adjusting for demographics, BMI, education, socioeconomic status, alcohol use, HIV status and viral suppression (for HIV+), to identify independent predictors of HTN, both overall and among HIV-positive persons. We excluded observations with missing data and accounted for clustering by household. R (version 3.1.2) was used for analysis [35].

**Ethics**

Heads of household provided written consent for all household members. Additionally, we obtained verbal consent from all adults and verbal parental consent for all children below 18 years of age. We waived a requirement for written consent for all participants because CHC activities involve no more than minimal harm to participants and involve no procedures for which written consent would otherwise be required, and because of limited literacy in our study population. Instead, we read the consent script orally to all participants, obtained verbal
agreement that participants understood the study, and answered any questions. We documented each participant’s consent using a unique biometric fingerprint, which we recorded electronically and stored securely. The study was approved by the Makerere University School of Medicine Research and Ethics committee; the Uganda National Council on Science and Technology; and the University of California, San Francisco Committee on Human Research. Each of these committees expressly reviewed and approved the waiver of written consent above.

Results

Participant Demographics

Across 20 Ugandan communities, 94,274 stable adult residents were enumerated: persons present in their current household for at least 6 months of the year. Of these residents, 65,544 (70%) attended a CHC and received screening for both HTN and HIV (Table 1). Overall, 59% of participants were female; the median age was 34, with an interquartile range of 24–48. 84% of participants were non-single, and 78% had no secondary education (including 71% of men and 83% of women). More men than women (38% vs. 12%) reported alcohol use. Overweight and obesity were higher in females (18% and 5%, respectively) than males (8% and 1%, respectively). Diabetes prevalence was low among both genders (1%). HIV prevalence was 5% overall, and was slightly higher in females (6%) than males (5%).

Hypertension prevalence, awareness, treatment and control

Overall, 8,650 participants had HTN, representing 14% prevalence (women: 13%; men: 15%; Table 1). Normalized to WHO world standard population distribution [34], HTN prevalence was 17% overall (women: 16%; men: 17%). In total, 8,021/ 8,650 participants (93%) met HTN criteria based on CHC BP screening while 629/8,650 (7%) reported a previous HTN diagnosis and current HTN medication use but had a negative HTN screen. Among the 8,021 participants with a positive HTN screen, 66% had Stage 2 HTN. Only 21% of hypertensive adults were aware of their diagnosis (women: 28%; men: 12%). Of those aware of their HTN, only 15% reported taking anti-hypertensive medication, and of persons taking medications, only 50% were normotensive (Table 1).

Predictors of Hypertension in the Overall Population

Risk factors for HTN included Eastern region residence, male gender, older age, no education (as compared to primary education), alcohol use, and higher BMI (Table 2). However, the odds of HTN were 1.2-fold higher among HIV negative persons compared to HIV positive persons (95% CI: 1.1–1.4).

Prevalence and Predictors of Hypertension in the HIV+ Population

The prevalence of HTN was greater among HIV-negative adults (14%) than among HIV-positive adults (11%). Among HIV-positive adults with HTN, 20% reported prior knowledge of HTN, and 14% reported taking medication. Similar to the overall population, 46% of HIV-positive adults with HTN achieved BP control with anti-hypertensive medications. After multivariate adjustment, significant predictors of HTN among persons with HIV were Eastern region residence; older age; no education (as compared to primary education); higher wealth index (income in top two quintiles); and higher BMI. Viral suppression of HIV did not significantly predict HTN (adjusted OR 1.1; 95% CI: 0.8–1.4).
### Table 1. Participant Demographics and Hypertension Prevalence, Treatment and Control.

| Region           | Overall N = 65,544, n(%) | Women N = 38,424, n(%) | Men N = 27,120, n(%) |
|------------------|--------------------------|------------------------|---------------------|
| **Region**       |                          |                        |                     |
| Eastern Uganda   | 33,342 (51%)             | 19,294 (50%)           | 14,048 (52%)        |
| Western Uganda   | 32,202 (49%)             | 19,130 (50%)           | 13,072 (48%)        |
| **Age (years)**  |                          |                        |                     |
| 18–29            | 25,360 (39%)             | 14,912 (39%)           | 10,448 (39%)        |
| 30–44            | 20,570 (31%)             | 12,296 (32%)           | 8,274 (31%)         |
| 45–59            | 11,599 (18%)             | 6,655 (17%)            | 4,944 (18%)         |
| ≥60              | 8,015 (12%)              | 4,561 (12%)            | 3,454 (13%)         |
| **Marital status** |                      |                        |                     |
| Single           | 10,344 (16%)             | 3,896 (10%)            | 6,448 (24%)         |
| Non-Single       | 55,108 (84%)             | 34,486 (90%)           | 20,622 (76%)        |
| **Education level** |                    |                        |                     |
| No education     | 13,043 (20%)             | 9,869 (26%)            | 3,174 (12%)         |
| Primary or less  | 37,933 (58%)             | 21,813 (57%)           | 16,120 (60%)        |
| Any secondary or beyond | 14,492 (22%) | 6,710 (17%) | 7,782 (29%) |
| **Alcohol use**  |                          |                        |                     |
| No               | 50,843 (78%)             | 33,956 (88%)           | 16,887 (62%)        |
| Yes              | 14,679 (22%)             | 4,460 (12%)            | 10,219 (38%)        |
| **BMI (kg/m²)**  |                          |                        |                     |
| <18 (underweight)| 10,112 (16%)             | 4,634 (13%)            | 5,478 (21%)         |
| ≥18–<25 (normal) | 41,926 (67%)             | 23,786 (65%)           | 18,140 (70%)        |
| ≥25–<30 (overweight)| 8,622 (14%) | 6,489 (18%) | 2,133 (8%) |
| ≥30 (obese)     | 2,038 (3%)               | 1,751 (5%)             | 287 (1%)            |
| **Diabetes**    |                          |                        |                     |
| Pre-Diabetes     | 7,303 (11%)              | 4,228 (11%)            | 3,075 (11%)         |
| Diabetes         | 521 (1%)                 | 285 (1%)               | 236 (1%)            |
| HIV+             | 3,545 (5%)               | 2,304 (6%)             | 1,241 (5%)          |
| **Hypertension**|                          |                        |                     |
| Hypertensive by BP | 8,021 (13%)  | 4,247 (12%)            | 3,774 (15%)         |
| Stage 1          | 2,718 (34%)              | 1,240 (29%)            | 1,478 (39%)         |
| Stage 2          | 5,303 (66%)              | 3,007 (71%)            | 2,296 (61%)         |
| Hypertensive by history | 629 (1%)  | 487 (1%)               | 142 (1%)            |
| Aware of hypertension | 1,797 (21%)  | 1,345 (28%)            | 452 (12%)           |
| Receiving medication | 1,260 (15%)  | 949 (20%)              | 311 (8%)            |
| BP controlled    | 629 (50%)                | 487 (51%)              | 142 (46%)           |
| BP uncontrolled  | 631 (50%)                | 462 (49%)              | 169 (54%)           |

Pre-Diabetes: Random blood sugar >7 mmol/L but ≤ 11 mmol/L; Diabetes: Random blood sugar >11 mmol/L; BP: blood pressure; Hypertensive by BP: Systolic BP ≥140 mmHg or Diastolic BP ≥90 mmHg on 3/3 readings; Hypertensive by history: self-reported hypertensive, on anti-hypertensive medications and negative by BP criteria.

N = number of participants; Missing values were excluded from analysis.

| Region       | Women N = 38,424, n(%) | Men N = 27,120, n(%) |
|--------------|------------------------|----------------------|
| Eastern Uganda | 19,294 (50%)           | 14,048 (52%)         |
| Western Uganda | 19,130 (50%)           | 13,072 (48%)         |

doi:10.1371/journal.pone.0156309.t001
Discussion

We report a 14% overall adult prevalence of HTN in a large Ugandan population sample. We also found low awareness of HTN (21%), infrequent use of anti-hypertensive medication (15%), and suboptimal levels of blood pressure control in persons on medication (50% of users; 7% of all persons with HTN). In the HIV-positive population, results were similar: HIV prevalence was 11%, only 20% of adults were aware of their diagnosis, 14% were on treatment, and 46% were of these normotensive (6% of all persons with HTN). These stark results are

Table 2. Predictors of Hypertension in multivariable analysis.

| Variable                      | Among all Adultsa | Among HIV+ Adultsb |
|-------------------------------|------------------|-------------------|
|                               | Adj. Odds Ratio (95%CI) | p-value | Adj. Odds Ratio (95%CI) | p-value |
| **Region**                    |                  |                   |                   |         |
| Western Uganda (ref)          | -                | -                 | -                 | -       |
| Eastern Uganda                | 1.26 (1.2, 1.3)  | <0.0001           | 1.34 (1.0, 1.7)   | 0.027   |
| **Sex**                       |                  |                   |                   |         |
| Female (ref)                  | -                | -                 | -                 | -       |
| Male                          | 1.23 (1.2, 1.3)  | <0.0001           | 1.20 (0.9, 1.6)   | 0.23    |
| **Age**                       |                  |                   |                   |         |
| 18–29 (ref)                   | -                | -                 | -                 | -       |
| 30–44                         | 2.27 (2.1, 2.5)  | <0.0001           | 2.21 (1.4, 3.6)   | 0.0015  |
| 45–59                         | 5.58 (5.1, 6.1)  | <0.0001           | 4.65 (2.8, 7.7)   | <0.0001 |
| 60+                           | 12.66 (11.6, 13.9)| <0.0001          | 11.82 (6.6, 21.3) | <0.0001 |
| **Education Level**           |                  |                   |                   |         |
| Less than primary (ref)       | -                | -                 | -                 | -       |
| Primary                       | 0.86 (0.8, 0.9)  | <0.0001           | 0.70 (0.5, 1.0)   | 0.024   |
| More than primary             | 0.96 (0.9, 1.1)  | 0.40              | 0.85 (0.6, 1.2)   | 0.41    |
| **Socio-economic Status**     |                  |                   |                   |         |
| 1st Wealth quintile (ref)     | -                | -                 | -                 | -       |
| 2nd Wealth quintile           | 0.96 (0.9, 1.1)  | 0.40              | 1.09 (0.7, 1.7)   | 0.69    |
| 3rd Wealth quintile           | 0.99 (0.9, 1.1)  | 0.84              | 1.30 (0.9, 2.0)   | 0.22    |
| 4th Wealth quintile           | 1.02 (0.9, 1.1)  | 0.65              | 1.64 (1.1, 2.4)   | 0.013   |
| 5th Wealth quintile           | 0.99 (0.9, 1.1)  | 0.83              | 1.68 (1.1, 2.5)   | 0.013   |
| **Alcohol Use**               |                  |                   |                   |         |
| No (ref)                      | -                | -                 | -                 | -       |
| Yes                           | 1.30 (1.2, 1.4)  | <0.0001           | 1.09 (0.8, 1.5)   | 0.57    |
| **BMI (kg/m²)**               |                  |                   |                   |         |
| Normal Weight or Underweight (ref) | -               | -                 | -                 | -       |
| Overweight                    | 1.90 (1.8, 2.0)  | <0.0001           | 1.55 (1.1, 2.2)   | 0.016   |
| Obese                         | 2.99 (2.7, 3.4)  | <0.0001           | 2.91 (1.6, 5.3)   | 0.0004  |
| **HIV Status**                |                  |                   |                   |         |
| Negative (ref)                | -                | -                 | -                 | -       |
| Positive                      | 0.82 (0.7, 0.9)  | 0.0022            | -                 | -       |
| **Viral suppression (if HIV+, viral load ≤ 500 copies/mL)** | | | | |
| No (ref)                      | -                | -                 | -                 | -       |
| Yes                           | -                | -                 | 1.07 (0.8, 1.4)   | 0.62    |

*Analysis restricted to all adults without missing data (N = 54,598)

*Analysis restricted to all HIV+ adults without missing data (N = 2,599)

doi:10.1371/journal.pone.0156309.t002
consistent with other studies in Ugandan populations [8,9,25–27,36–39], and other Sub-Saharan African populations [19,40–46], that have reported a HTN prevalence of 15–50%.

We found substantial differences in HTN control by gender. HTN awareness was higher in women than men (28% vs. 12%), consistent with other Ugandan data [26,36]. This result may be due to women more frequently engaging with health services because of their maternal and child care roles [43]. Adjusted for age according to the WHO world standard population, the overall prevalence of HTN is 17%, which is lower than some recent studies [9], but comparable to rates in the United Kingdom (18.6%) [46], and other developed countries [47–49]. These results suggest a large and unaddressed burden of HTN in Uganda that requires concerted screening and control efforts in both HIV-positive persons and the nation overall. Meeting this need requires health system strengthening efforts such as community health campaigns or community outreach, an approach validated in the control of asymptomatic diseases such as HIV and HTN [28,50,51].

We report HTN risk factors that parallel prior Ugandan findings [8,9,38], as well as data from developed nations [3,47,52]. Risk factors include male gender and older age, as well as modifiable factors such as overweight and obesity; alcohol consumption; having no primary education; and residence in Eastern Uganda. All six of these factors were predictive of HTN in the general population, but male gender and alcohol consumption were not predictive of HTN in persons with HIV. Conversely, high socioeconomic status (top two income quintiles) was associated with HTN in HIV-positive persons only. These discrepancies may reflect a difference in sample size (and hence statistical power) between the two groups, given that the association between alcohol use, male gender, and HTN risk is well-understood [3, 53, 54]. The association between Eastern Ugandan residence and HTN may be related to unmeasured confounders, such as differences in dietary salt intake between the two regions.

These results suggest an opportunity to employ HTN treatment and prevention programs in Uganda that have been successful in other countries, e.g., alcohol and salt limitation, and frequent exercise [3,53,54]. As Uganda’s economic development accelerates, greater primary education may increase HTN awareness and control. However, rising wealth indices may conversely create diet and exercise changes that could increase HTN rates. Thus, more research is needed on the impact of education and socio-economic status on HTN in Sub-Saharan Africa, both in the general population and among persons living with HIV.

Notably, HIV-positive status was associated with a lower risk of HTN (11% prevalence among HIV-negative persons, but 14% among HIV+ persons), consistent with other studies in Sub-Saharan Africa, and in Uganda specifically [8,18,19]. After controlling for other risk factors, the odds of HTN were 20% higher for HIV-negative persons than HIV-positive persons. This result eludes clear biological explanation. Antiretroviral medications (and HIV itself) may raise BP via physiologic changes such as glucocorticoid and insulin resistance [55,56]. Moreover, studies in developed countries have observed higher blood pressure in persons with HIV than HIV-negative controls [14,15].

Several possible explanations are plausible, and will need further study. First, SEARCH Study community health campaigns measure BP just prior to testing for HIV. HIV-positive persons who know their HIV status prior to testing may have lower anxiety (and thus BP). Biological mechanisms are also plausible. Genetic factors (e.g. CCR5 mutation) are protective against HIV infection [57]. Similarly, genetic factors (both predisposing and protective) have been linked to HTN [58]. It is thus possible that genetic factors predisposing to HIV infection might be concomitantly protective against HTN. Alternatively, the observed negative association between HIV and HTN may be due to a paucity of persons suffering from both conditions (due to survival bias attributable to mortality). A longitudinal study tracking populations
positive for HTN alone; HIV alone; or the two conditions concurrently, could shed light on how these risk factors interact.

Among HIV-positive adults, we found no substantial association between HTN and viral suppression. While current evidence suggests that circulating viremia in HIV infection can cause inflammatory and endovascular changes that promote HTN [59], antiretroviral medications themselves may directly cause or precipitate HTN [17,56]. It is therefore possible that persons with HIV who achieve viral suppression through ART concurrently decrease risk of HTN (due to control of viremia) and increase of HTN via ART medications: two opposing effects that may offset one another. Future longitudinal studies could investigate this hypothesis by investigating HIV-positive persons on ART who fail to achieve viral suppression; or, conversely, HIV-positive persons who achieve viral suppression without ART (i.e., elite suppressors).

Our study has two important limitations. It was cross-sectional: we could not assess temporal relationships between risk factors and HTN outcomes. We also could not adjust for certain unmeasured potential confounders, including: physical activity, smoking, renal function, lipid levels and family history of HTN. However, our previous work suggests that smoking in this population is relatively uncommon (12–18%) [26,27], and that tobacco use is not significantly associated with HTN [26]. Moreover, our study did adjust for many potential confounders, such as age, gender, education level, socio-economic status, alcohol use, BMI, and region.

We report a large burden of HTN in Uganda, which remains largely undiagnosed and uncontrolled in both HIV-positive persons and the general population. The risk factors for HTN in both groups appear to be similar to those described in developed countries, such as older age, male gender, obesity, and alcohol use. Although we found HIV infection to be negatively associated with HTN after adjusting for common risk factors, the burden of hypertensive disease in persons with HIV remains large and inadequately controlled. These results suggest that programs for HTN screening and control are urgently needed in Uganda. Increasing access to ART for HIV in Sub-Saharan Africa, along with improved socioeconomic opportunity and an aging population, will likely only increase the burden of HTN and other NCDs in the region. However, programs for universal screening and treatment of HIV offer a unique opportunity to screen for and educate on HTN in a population with minimal prior access to care [25–27]. Health systems in Sub-Saharan Africa could adapt these models as they work to respond to a growing NCD burden, while concurrently ensuring universal access to HIV screening and care.

Acknowledgments

Research reported in this manuscript was supported by Division of AIDS, NIAID of the National Institutes of Health under award number U01AI099959 and in part by the President’s Emergency Plan for AIDS Relief and Gilead Sciences. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, PEPFAR, or Gilead. The SEARCH project gratefully acknowledges the Ministries of Health of Uganda and Kenya, our research team, collaborators and advisory boards, and especially all communities and participants involved. We also thank the residents of the twenty SEARCH study communities across Uganda for their generous participation in our study.

Author Contributions

Conceived and designed the experiments: DH MRK DK MP VJ GC TC. Performed the experiments: DH MRK DK MP VJ GC TC JA DB FM PK. Analyzed the data: LB DH MRK DK MP
VJ GC TC. Contributed reagents/materials/analysis tools: DH MRK MP VJ GC TC JA DB FM PK LB DH. Wrote the paper: DH MRK MP VJ GC TC JA DB FM PK LB DH.

References

1. Global Health Risks: Mortality and Burden of Disease Attributable to Selected Major Risks. The World Health Organization, 2009. Available: http://www.who.int/healthinfo/global_burden_disease/GlobalHealthRisks_report_full.pdf.

2. Lloyd-Sherlock P, Ebrahim S, Grosskurth H. Is hypertension the new HIV epidemic? Int J Epidemiol. 2014; 43(1): 8–10. doi: 10.1093/ije/dyu019 PMID: 24491955

3. A Global Brief on Hypertension. The World Health Organization, 2013. Available: http://ish-world.com/downloads/pdf/global_brief_hypertension.pdf.

4. Global Burden of Disease. Projections of mortality and burden of disease, 2002–2030. The World Health Organization, 2014. Available: http://www.who.int/topics/global_burden_of_disease/en/.

5. Dalal S, Beunza JJ, Volmink J, Adebamowo C, Bajuniwe F, Njeleleka M et al. Non-communicable diseases in sub-Saharan Africa: what we know now. Int J Epidemiol 2011; 40: 885–901. doi: 10.1093/ije/dyr056 PMID: 21527446

6. Opie LH, Seedat YK. Hypertension in Sub-Saharan African Populations. Circulation 2005; 112: 3562–8. PMID: 16330697

7. Helelo TP, Gelaw YA, Adane AA. Prevalence and associated factors of hypertension among adults in Durame Town, Southern Ethiopia. PLoS One 2014. doi: 10.1371/journal.pone.0112790

8. Kayima J, Nankabirwa J, Sinabulya I, Nakibuuka J, Zhu X, Rahman M, et al. Determinants of hypertension in a young adult Ugandan population in epidemiological transition- the MEPI-CVD study. BMC Public Health 2015; (15: ) 830.

9. Guwatudde D, Mutungi G, Wesonga R, Kajura R, Kasula H, Muwonge J. The Epidemiology of Hypertension in Uganda: Findings from the National Non-Communicable Diseases Risk Factor Survey. PLoS One 2015. doi: 10.1371/journal.pone.0138991

10. UNAIDS Report on the Global AIDS Epidemic 2013. UNAIDS, 2013. Available: http://www.unaids.org/sites/default/files/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf.

11. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338(13): 853–60. PMID: 9516219

12. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352(9142): 1725–30.

13. Petersen M, Yiannoutsos CT, Justice A, Egger M. Observational research on NCDs in HIV-positive populations: conceptual and methodological considerations. J Acq Immun Def Synd. 2014; 67 Suppl 1: S8–16.

14. Mattana J, Siegal FP, Sankaran RT, Sinhal PC. Absence of age-related increase in systolic blood pressure in ambulatory patients with HIV infection. Am J Med Sci 1999; 317(4): 232–7. PMID: 10210358

15. Gazzaruso C, Bruno R, Garzaniti A, Giordanetti S, Fratino P, Sacchi P, et al. Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome. J Hypertens 2003; 21(7): 1377–82. PMID: 12817187

16. Jenico K, Knobel H, Montero M, et al. Hypertension in HIV-infected patients: prevalence and related factors. Am J Hypertens 2005; 18(11): 1396–401. PMID: 16280270

17. Bergersen BM, Sandvik L, Dunlop O, Birkeland K, Bruun JN. Prevalence of hypertension in HIV-positive patients on highly active retroviral therapy (HAART) compared with HAART-naive and HIV-negative controls: results from a Norwegian study of 721 patients. Eur J Clin Microbiol 2003; 22(12): 731–6.

18. Dillon DG, Gursadani D, Riha J, Ekoru K, Asiki G, Mayanja BN, et al. Association of HIV and ART with cardiometabolic traits in sub-Saharan Africa: a systematic review and meta-analysis. Int J Epidemiol 2012; 42(6): 1754–71.

19. Schutte AE, Schutte R, Huisman HW, van Rooyen JM, Fourie CM, Malan NT, et al., Are behavioural risk factors to be blamed for the conversion from optimal blood pressure to hypertensive status in Black South Africans? A 5-year prospective study. Int J Epidemiol 2012; 41(4): 1114–23. doi: 10.1093/ije/dys106 PMID: 22825590
20. Chillo P, Bakari M, Lwakatare J. Echocardiographic diagnoses in HIV-infected patients presenting with cardiac symptoms at Muhimbili National Hospital in Dar es Salaam, Tanzania. Cardiovasc J Afr. 2012; 23(2): 90–7. doi: 10.5830/CVJA-2011-060 PMID: 22331234

21. Schwart T, Magdi G, Steen TW, Sjaastad I. HIV as a risk factor for cardiac disease in Botswana: a cross-sectional study. Int Health. 2012; 4(1): 30–7. doi: 10.1016/j.inhe.2011.12.003 PMID: 24030878

22. Adewole OO, Eze S, Betiku Y, Anteyi E, Wada I, Ajuwon Z, et al. Lipid profile in HIV/AIDS patients in Nigeria. Afr Health Sci 2012; 10(2): 144–9.

23. Havlir D, Kamya M, Petersen M. Study Protocol: Sustainable East Africa Research in Community Health, 2015. Available: https://clinicaltrials.gov/ct2/show/NCT01864603.

24. Chamie G, Clark TD, Kabami J, Kadeke K, Ssemmondo E, Steinfeld R, et al. A hybrid mobile HIV testing approach for population-wide HIV testing in rural East Africa: an observational study. The Lancet HIV 2015; in press.

25. Chamie G, Kwarisiima D, Clark TD, Kabami J, Jain V, Geng EH et al. Leveraging Rapid Community-Based HIV Testing Campaigns for Non-Communicable Diseases in Rural Uganda. PLOS One 2012. doi: 10.1371/journal.pone.0043400

26. Kotwani P., Kwarisiima D, Clark TD, Kabami J, Geng EH, Jain V, et al. Epidemiology and awareness of hypertension in a rural Ugandan community: a cross-sectional study. BMC Public Health 2013; 13(1): 1151.

27. Kotwani P, Balzer LB, Kwarisiima D, Clark TD, Kabami J, Byonanebye DM, et al. Evaluating linkage to care for hypertension after community-based screening in rural Uganda. Trop Med Intl Health 2014; 19 (4) 459–68.

28. Chamie G, Kwarisiima D, Clark TD, Kabami J, Jain V, Geng EH, et al. Uptake of Community-Based HIV Testing during a Multi-Disease Health Campaign in Rural Uganda. PLoS ONE 2014. doi:10.1371/journal.pone.0084317

29. Uganda national policy guidelines for HIV voluntary counselling and testing. Uganda Ministry of Health, 2005. Available: http://www.who.int/hiv/pub/guidelines/uganda_art.pdf.

30. Jain V, Liegler T, Kabami J, Chamie G, Clark TD, Black D, et al. Assessment of population-based HIV RNA levels in a rural east African setting using a fingerprick-based blood collection method. Clin Infect Dis 2013: 56(4).

31. Whitworth JA, the World Health Organization International Society of Hypertension Writing Group. World Health Organization(WHO)/International Society of Hypertension(ISH) statement on management of hypertension. J Hypertens 2003; 21(11): 1983–92. PMID:14597836

32. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42(6): 1206–52. PMID: 14656957

33. Balen J, McManus DP, Li YS, Zhao ZY, Yuan LP, Utzinger J, et al. Comparison of two approaches for measuring household wealth via an asset-based index in rural and peri-urban settings of Hunan province, China. Emerg Themes Epidemiol 2010; 7(7): 1–7.

34. Ahmad OB, Boschi-Pinto C, Lopez AD, Murray CJL, Lozano R, Inoue M. Age Standardization of rates: A new WHO standard. The World Health Organization, 2001. Available: http://www.who.int/healthinfo/paper31.pdf.

35. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. Vienna, Austria, 2014. Available: www.R-project.org.

36. Maher D , Waswa L, Baisley K, Karabarinde A, Unwin N. Epidemiology of hypertension in low-income countries: a cross-sectional population-based survey in rural Uganda. J Hypertens 2011; 29(6): 1061–8. doi: 10.1097/HJH.0b013e3283466e90 PMID: 21505357

37. Musinguzi G, Nuwaha F. Prevalence, awareness and control of hypertension in Uganda. PLoS One 2013; 8(4): doi:10.1371/journal.pone.0062236

38. Wamala J.F, Karyabakabo Z, Ndungutse D, Guwatudde D. Prevalence factors associated with hypertension in Rukungiri district, Uganda—a community-based study. Afr J Health Sci, 2009. 9(3): 153–60. PMID: 20589143

39. Mayega RW, Makumbi F, Rutebemberwa E, Peterson S, Östenson CG, Tomson G, et al. Modifiable socio-behavioural factors associated with overweight and hypertension among persons aged 35 to 60 years in eastern Uganda. PLoS One 2012. doi: 10.1371/journal.pone.004763

40. Muluneh AT, Haileamlak A, Tessema F, Alemseged F, Woldemichael K, Asefa M, et al. Population based survey of chronic non-communicable diseases at gilgel gibe field research center, southwest ethiopia. Ethiop J Health Sci. 2013; 22(4): 7–18.

41. Kayima J, Wanyenze RK, Katamba A, Leontsini E, Nuwaha F. Hypertension awareness, treatment and control in Africa: a systematic review. BMC Cardiovasc Disord 2013; 13(1): 54.
42. Damasceno A, Azevedo A, Silva-Matos C, Prista A, Diogo D, Lunet N. Hypertension prevalence, awareness, treatment, and control in mozambique: urban/rural gap during epidemiological transition. Hypertension 2009; 54(1): 77–83. doi: 10.1161/HYPERTENSIONAHA.109.132423 PMID: 19470872

43. Addo J, Smeeth L, Leon DA. Hypertension in sub-saharan Africa: a systematic review. Hypertension 2007; 50(6): 1012–8. PMID: 17954720

44. Pereira M, Lunet N, Azevedo A, Barros H. Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries. J Hypertens 2009; 27(5): 963–75. PMID: 19402221

45. Twagirumukiza M, De Bacquer D, Kips JG, de Backer G, Stichele RV, Van Bortel LM. Current and projected prevalence of arterial hypertension in sub-Saharan Africa by sex, age and habitat: an estimate from population studies. J Hypertens 2011; 29(7) 1243–52. doi: 10.1097/HJH.0b013e328346995d PMID: 21540748

46. Twagirumukiza M, Van Bortel LM. Management of hypertension at the community level in sub-Saharan Africa (SSA): towards a rational use of available resources. J Hum Hypertens. 2011; 25(1): 47–56. doi: 10.1038/jhh.2010.32 PMID: 20336148

47. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 289(18): 2363–9. doi:10.1097/01.JAM.0000101340.60067.02 PMID: 12746359

48. Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension 2007; 49(1): 69–75. PMID: 17159087

50. Tumwesigye E, Wana G, Kasasa S, Muganz E, Nuwaha F. High uptake of home-based, district-wide, HIV counseling and testing in Uganda. AIDS Patient Care STDS 2010; 24(11): 735–41. doi: 10.1089/apc.2010.0096 PMID: 21067357

51. Menzies N, Abang B, Wanyenze R, Nuwaha F, Mugisha B, Coutinho A, et al. The costs and effectiveness of four HIV counseling and testing strategies in Uganda. AIDS 2009; 23(3): 395–401. doi: 10.1097/QAD.0b013e3282ee4b PMID: 19114865

52. Ford ES, Cooper RS. Risk Factors for Hypertension in a National Cohort Study. Hypertension 1991; 18 (5): 598–606. PMID: 1937662

53. Nissinen A, Tuomilehto J, Korhonen HJ, Piha T, Salonen JT, Puska P. Ten-Year Results of Hypertension Care in the Community: Follow-Up of the North Karelia Hypertension Control Program. Am Journal Epidemioil 1998; 127(3): 488–99.

54. Appel LJ, Champagne CM, Harsha DW, Cooper LS, Obarzanek E, Elmer PJ, et al. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA 2003; 289(16): 2083–93. PMID: 12709466

55. Aoun S, Ramos E. Hypertension in the HIV-infected patient. Curr Hypertens Rep 2000; 2(5): 478–81. PMID: 10995524

56. Seaberg EC, Muñoz A, Lu M, Detels R, Margolick JB, Riddler SA, et al. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS 2005; 19(9): 953–60. PMID: 15905677

57. Piacentini L, Biasin M, Fenizia C, Clerici M. Genetic correlates of protection against HIV infection: the ally within. J Intern Med 2008; 265(1): 110–24.

58. Kurtz TW, Spence MA. Genetics of essential hypertension. Am J Med 1993; 94(1): 77–84. PMID: 8420305

59. Palella FJ, Phair PJ. Cardiovascular disease in HIV infection. Curr Opin HIV AIDS 2011; 6(4): 266–71. doi: 10.1097/COH.0b013e328347876c PMID: 21546831